- Company
- Keytruda coverage expansion plan back to MSD for revision
- by Eo, Yun-Ho Sep 4, 2020 06:53am
- Regarding the Keytruda coverage expansion, the South Korean authority passed the ball back to MSD Korea. The pharmaceutical industry sources reported Health Insurance Review and Assessment Service (HIRA) informed MSD on Sept. 2 about PD-1 inhibitor Keytruda’s (pembrolizumab) financial burden reduction plan the Cancer Deliberation Commi
- Company
- Celebrex barrier still too high for NSAID Acelex
- by Nho, Byung Chul Sep 4, 2020 06:52am
- The 22nd Korean-made novel drug (Bio-venture No. 1) and a nonsteroidal anti-inflammatory drug (NSAID) for arthritis Acelex (polmacoxib) seems to be stuck in a box pattern, struggling to narrow the sales gap with its biggest competitor Celebrex (celecoxib). IQVIA data found Acelex has generated 598 million won, 4.01 billion won, 4.78 bill
- Company
- Galderma Korea appoints Younhee Kim as the new CEO
- by Eo, Yun-Ho Sep 3, 2020 12:55pm
- Galderma Korea has appointed Younhee Kim, former general manager of the Medical Solution Division, as the new CEO. According to related industries, CEO Kim started official business as the official president on the October 1st. Rene Wipperich, former CEO of Galderma's Korean subsidiary for two years from September 2018, has been confirmed
- Company
- Sales of immunotherapy for Cancer are ↑18 times in 4 years
- by An, Kyung-Jin Sep 2, 2020 06:19am
- Immunotherapy for Cancer is expanding rapidly in the domestic pharmaceutical market. The domestic immune checkpoint inhibitor market started with Yervoy (Ipilimumab), Keytruda (Pembrolizumab), and Opdivo (Nivolumab), and generics such as Tecentriq (Atezolizumab) and Imfinzi (Durvalumab) were added one after another, sales increased by 18 t
- Company
- AZ Korea Director Chon as a new Country President Indonesia
- by Eo, Yun-Ho Sep 2, 2020 06:18am
- Chon Sewhan, a director at AstraZeneca Korea, has been promoted as a Country President at PT. AstraZeneca Indonesia The industry sources reported the current Cardiovascular, Renal and Metabolic Diseases (CVRM) Business Unit Director, Chon Sewhan, has been appointed as a Country President Indonesia as of Sept. 1. Started off his career
- Company
- Forxiga by AstraZeneca appeals against Dong-A ST
- by Kim, Jin-Gu Sep 2, 2020 06:18am
- AstraZeneca, which failed in the first round of the patent dispute over the SGLT-2 inhibitor-based diabetes treatment, Forxiga (Dapagliflozin), launched a counterattack against Dong-A ST. It disagrees with the trial decision of the Patent Tribunal, who sided with the generic company, and filed a lawsuit to the Patent Court of Korea to canc
- Company
- Indication of Alunbrig expanded as ALK-positive lung cancer
- by Sep 2, 2020 06:18am
- The indication has been expanded as the first line treatment of Takeda Pharmaceutical Korea's lung cancer treatment, Alunbrig. Takeda Pharmaceutical Korea (CEO Moon Hee-seok) announced on the 28th that The MFDS approved Alunbriq (Brigatinib), an anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer drug, to expand its indica
- Company
- Now, a transition of power in the contraceptive market
- by Sep 1, 2020 06:13am
- The domestic over-the-counter (OTC) pre-contraceptive market, which was almost monopolized by imported finished products, is showing mixed trend. Sales of top-tier products such as Myvlar have been sold out for a long period of time, resulting in a sharp decrease in sales, and recently released products are fiercely competing, causing changes.
- Company
- “Cosidering PPI when prescribing NOAC in high-risk patient"
- by Eo, Yun-Ho Sep 1, 2020 06:13am
- Already, it has been ten years since new oral anticoagulant (NOAC) has launched in the South Korean market. Experts are actively discussing the practical use of NOAC as relevant prescription records have been accumulated. Regarding the off-label prescription of the drug, the interest has heightened recently on optimizing the dose and ble
- Company
- GC-Novartis report COVID-19 cases, all other test negative
- by Kim, Jin-Gu Sep 1, 2020 06:12am
- Although confirmed cases of COVID-19 were reported from GC Pharma and Novartis Korea, sources confirmed others in the companies were not further infected. According to pharmaceutical industry sources on Aug. 28, all workers, who had a close contact with the confirmed cases in the same department or in the vicinity at GC Pharma and Novartis K
